Clinical trials: Non-HIV
Human Immunodeficiency Virus
Prospective Observational Epidemiologic Study of Maraviroc's Safety
The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.
- Trial name
- POEM (NCT00665561)
- Testing
- Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
- Where
- 269 sites in United States, Belgium and 9 more
- Volunteers
- 2,500 people
- Sponsor
- ViiV Healthcare
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human…
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03220022
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 19 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Hiv, HIV/AIDS
AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial
AllyQuest (AQ) is a theory-informed smart phone application that supports HIV medication adherence for young men who have sex with men and young transgender women who have sex with men (YMSM/YTW) via behavior change, social…
- Conditions
- Hiv, HIV/AIDS, Medication Adherence, Sexual Behavior
- Trial name
- AQ2 (NCT03916484)
- Testing
- AllyQuest HIV Medication Adherence app-delivered intervention, AllyQuest HIV Medication Adherence app-delivered intervention + NSC
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child transmission (MTCT) of HIV.
- Trial name
- P1060 (NCT00307151)
- Testing
- Lamivudine, Lopinavir/ritonavir, Nevirapine
- Where
- 10 sites in India, Malawi and 5 more
- Volunteers
- 452 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
HIV
Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV
To examine the effects of Mindfulness-Based Stress Reduction (MBSR) and education groups on HIV (Human Immunodeficiency Syndrome) infection. Key outcomes include CD4 and viral load, stress hormones, depression and quality of life.
- Trial name
- NCT00271856
- Testing
- Mindfulness-Based Stress Reduction (MBSR), HIV-education and self-management workshop
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of California, San Francisco
HIV Infections
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
The aim of the study is to establish if human immunodeficiency virus type 1 (HIV-1) infected adult participants with current virologic suppression on a >=3-drug tenofovir alafenamide (TAF) based regimen (TBR) remain suppressed…
- Trial name
- NCT03446573
- Testing
- DTG + 3TC, TAF based regimen (TBR)
- Where
- 133 sites in United States, Australia and 8 more
- Volunteers
- 743 people
- Sponsor
- ViiV Healthcare
HIV Infections
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
This is an open-label, single-center, single group, non-randomized, two-period, single sequence, mass balance study which will enroll 6 healthy male participants.
- Trial name
- NCT04507321
- Testing
- GSK3640254 Oral tablet, [14C]-GSK3640254 intravenous infusion, [14C]-GSK3640254 powder
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1
Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection
Aim of the study is to gain more knowledge about efficacy of CELSENTRI® in daily clinical practice and obtain information about the quality of life of patients using CELSENTRI®.
- Trial name
- NCT00850395
- Testing
- maraviroc
- Volunteers
- 79 people
- Sponsor
- ViiV Healthcare
Substance Use, HIV Infections
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system.
- Conditions
- Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis)
- Trial name
- NCT04134767
- Testing
- Health Linkage, Overdose Education
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- April M Young
HIV Prevention, Transgender Health
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012. Drug concentrations after receipt of oral Truvada for HIV Pre Exposure Prophylaxis (or PrEP) appeared to be…
- Trial name
- I-BrEATHe (NCT04050371)
- Testing
- 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Group B Streptococcal Infection
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
A randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women…
- Trial name
- NCT04596878
- Testing
- GBS-NN/NN2
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
HIV Infections
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs.
- Trial name
- NCT00515827
- Testing
- Raltegravir (MK-0518)
- Where
- 20 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Exercise, Oxidative Stress and HIV
The purpose of this study is to compare oxidative stress markers and the immunologic characteristics of HIV-infected and non-HIV subjects during a bout of moderate aerobic exercise followed by resistance exercises
- Trial name
- NCT00950937
- Where
- Brazil
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
HIV Infections
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g.
- Trial name
- NCT00876733
- Where
- 66 sites in Germany
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
HIV Infection
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation.
- Trial name
- EraMune02 (NCT00976404)
- Testing
- DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Robert L. Murphy